ŠMAK, Pavel, Selvaraj CHANDRABOSE, Igor TVAROŠKA a Jaroslav KOČA. Pan-selectin inhibitors as potential therapeutics for COVID-19 treatment: in silico screening study. Glycobiology. Oxford University Press, 2021, roč. 31, č. 8, s. 975-987. ISSN 0959-6658. Dostupné z: https://dx.doi.org/10.1093/glycob/cwab021.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Pan-selectin inhibitors as potential therapeutics for COVID-19 treatment: in silico screening study
Autoři ŠMAK, Pavel (203 Česká republika, domácí), Selvaraj CHANDRABOSE (356 Indie, domácí), Igor TVAROŠKA (703 Slovensko, domácí) a Jaroslav KOČA (203 Česká republika, garant, domácí).
Vydání Glycobiology, Oxford University Press, 2021, 0959-6658.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 10400 1.4 Chemical sciences
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 5.954
Kód RIV RIV/00216224:14310/21:00123502
Organizační jednotka Přírodovědecká fakulta
Doi http://dx.doi.org/10.1093/glycob/cwab021
UT WoS 000697400400009
Klíčová slova anglicky COVID-19; docking; pan-selectin inhibitors; selectins; virtual screening
Štítky rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Marie Šípková, DiS., učo 437722. Změněno: 5. 1. 2022 15:40.
Anotace
Coronavirus disease 2019 (COVID-19) has spread rapidly throughout the globe. The spectrum of disease is broad but among hospitalized patients with COVID-19, respiratory failure from acute respiratory distress syndrome is the leading cause of mortality. There is an urgent need for an effective treatment. The current focus has been developing novel therapeutics, including antivirals, protease inhibitors, vaccines and targeting the overactive cytokine response with anti-cytokine therapy. The overproduction of early response proinflammatory cytokines results in what has been described as a "cytokine storm" is leading eventually to death when the cells fail to terminate the inflammatory response. Accumulating evidence shows that inflammatory cytokines induce selectin ligands that play a crucial role in the pathogenesis of inflammatory diseases by mediating leukocyte migration from the blood into the tissue. Thus, the selectins and selectin ligands represent a promising therapeutic target for the treatment of COVID-19. In this paper, potential pan-selectin inhibitors were identified employing a virtual screening using a docking procedure. For this purpose, the Asinex and ZINC databases of ligands, including approved drugs, biogenic compounds and glycomimetics, altogether 923,602 compounds, were screened against the P-, L- and E-selectin. At first, the experimentally confirmed inhibitors were docked into all three selectins' carbohydrate recognition domains to assess the suitability of the screening procedure. Finally, based on the evaluation of ligands binding, we propose 10 purchasable pan-selectin inhibitors to develop COVID-19 therapeutics.
Návaznosti
EF17_050/0008496, projekt VaVNázev: MSCAfellow@MUNI
LM2018140, projekt VaVNázev: e-Infrastruktura CZ (Akronym: e-INFRA CZ)
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, e-Infrastruktura CZ
LQ1601, projekt VaVNázev: CEITEC 2020 (Akronym: CEITEC2020)
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020
VytisknoutZobrazeno: 7. 10. 2024 03:17